engraftment
play

Engraftment Annette Trickett Principal Scientist | BMT Laboratory | - PowerPoint PPT Presentation

Engraftment Annette Trickett Principal Scientist | BMT Laboratory | NSW Health Pathology, Randwick Hospitals 25 May 2018 Scope Aim: Provide a better understanding of the engraftment timeline and impacting factors Objectives: Define


  1. Engraftment Annette Trickett Principal Scientist | BMT Laboratory | NSW Health Pathology, Randwick Hospitals 25 May 2018

  2. Scope Aim: • Provide a better understanding of the engraftment timeline and impacting factors Objectives: • Define haematological reconstitution • What can affect engraftment? • Recovery of immune function • Failure of engraftment and rescue strategies

  3. Haematological reconstitution • Recovery of neutrophil and platelet counts after the nadir induced by conditioning therapy • Sustained absolute neutrophil count (ANC) ≥ 0.5 x 10 9 /L – 1 st of 3 consecutive days • Unsupported platelet count ≥ 20 x 10 9 /L – 7 days after last platelet infusion • Recovery of neutrophil and platelet counts after the nadir induced by conditioning therapy • Time of engraftment = Number of days between HPC infusion and neutrophil or platelet recovery

  4. Stem cell journey • HPC transplant (intravenous infusion) • Stem cells circulate via the blood stream • “Home” to bone marrow niches within 24 hrs • Proliferate & differentiate to generate mature blood cells

  5. Stem cell homing (1) Migrate from circulation to marrow cavity • Roll along vessel wall • Attach to endothelium via adhesion molecules and chemo attractants (like “grip ball”) • Migrate through endothelial cells • Lodge into BM niche which provides the environment for proliferation

  6. Stem cell homing (2) Annals of NY Acad Sci 2014: 301; 119-128

  7. HPC proliferation & differentiation https://commons.wikimedia.org /w/index.php?curid=9420824

  8. Engraftment Mature blood cells migrate from the marrow niche into the blood vessels https://basicmedicalkey.com/hemopoiesis/

  9. Inter-site comparison - ANC Neutrophil recovery after autologous HPC-A transplant NSW UK 8 Median = 11 days Median = 12 days 40 7 vCD34 Dose (x10 6 /kg) (thawed count) 35 6 Days to ANC  0.5x10 9 /L 30 5 25 4 20 3 15 2 10 1 5 0 0 A B C D E F G H I J K L BMT Program BMT Network 2018 BMT 2017: 52; 992

  10. Inter-site comparison - Plt Platelet recovery after autologous HPC-A transplant NSW UK 8 130 Median = 16 days Median = 24 days 120 7 vCD34 Dose (x10 6 /kg) (thawed count) 110 100 6 Days to PLT  20x10 9 /L 90 5 80 70 4 60 50 3 40 2 30 20 1 10 0 0 A B C D E F G H I J K L BMT Program BMT Network 2018 BMT 2017: 52; 992

  11. Effect of donor & HPC source Bone Marrow Transplantation 2013: 48; 691-697

  12. Differential WBC recovery % Recovery Bone Marrow Transplantation 2009: 44; 457-462

  13. Recovery of immune function Donor type affects rate of immune function recovery - Autologous > Related allogeneic > Unrelated allogeneic Innate (non-specific) immunity recovers within months – Monocytes > Granulocytes > NK cells Adaptive (cellular & humoral) immunity takes at least 1-2 years – Expansion of infused donor T cells – Thymic T cell generation from donor HPC (needs functional thymus) – B cells recover by 6-9 months; function dependent on T cell help – Hence prolonged risk of infection 10.1182/a .1182/ash sheduc ucati tion on-20 2015.1. 15.1.215 215 ASH Education Book December 5, 2015 vol. 2015 no. 1 215-219

  14. Graft failure Primary – Failure to attain sustained ANC ≥ 0.5 x 10 9 /L, Plt ≥ 20 x 10 9 /L, RBC transfusion independence – Failure to achieve donor chimerism Secondary – Loss of graft / donor chimerism – Usually within 6 months but can occur later • Higher risk in non-malignant disorders • Often precedes relapse in malignant disorders

  15. Incidence of graft failure • Autologous < 1% • Allogeneic HLA matched sibling donor 1 – 2% • Risk factors: – HLA or ABO group mismatch – Donor: female, older age – Non-malignant disorder, # blood transfusions – Conditioning regimen – HPC cell source, dose, quality & manipulation – Post transplant myelosuppresive drugs – Infection

  16. Rescue strategies • Growth factors, e.g. G-CSF • Increase immunosuppression • Donor lymphocyte infusions (DLI) • Stem cell boost • HPC transplant (same or different donor) • Autologous HPC rescue (cryopreserved cells)

  17. Summary • Engraftment: – 1 st of 3 consecutive days with blood ANC ≥ 0.5 x 10 9 /L – Platelet count ≥ 20 x 10 9 /L, 7 days after last platelet infusion • Many factors influence engraftment rate • Graft failure rate is low in autologous & MSD transplant • Recovery of immune function takes months – years

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend